Tests EVO756 for preventing migraine in adults
Tests EVO756 against placebo to prevent migraine in adults aged 18 to 64.
Plain-language title generated from the registry record
Registry title: Study of EVO756 in Adults With Migraine
Key facts
- Where
- Québec, CanadaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine who have tried preventive migraine treatments that did not work. It tests EVO756 against placebo.
- Age
- 18 to under 65 years (18 to 64 years).
- Sex
- All sexes can join.
- Disease stage
- Migraine with or without aura, as defined by ICHD-3 criteria.
- Earlier treatment
- Must have had no success with earlier preventive migraine treatments. Must not be using a migraine preventive treatment now.
Main reasons for not taking part
- Difficulty telling migraine apart from other headache types
- Other primary headache disorders
- Use of certain medications
- Any clinically significant medical, psychiatric, neurological, cardiovascular or laboratory abnormalities
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT07616128, who can take part
Where in Canada
- Centre de Recherche St-LouisQuébec, CanadaContact: EVO756-MIG001 Research SiteTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Evommune, Inc.
- Trial code
- NCT07616128
- Record updated
- 4 November 2026
- Original description
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.Read full original descriptionShow less
A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of EVO756 for the Prevention of Migraine in Adults
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Inclusion: Adults aged 18 to <65 years; Migraine with or without aura, per ICHD-3 criteria; History of failure with prior preventive migraine treatments; Not currently using migraine preventive therapy.
Exclusion: Use of certain medications; Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders; Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities.